70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart(Université Libre de Bruxelles), Emiel J. Rutgers(Oncode Institute), Coralie Poncet(European Organisation for Research and Treatment of Cancer), Laura van ‘t Veer, Jean‐Yves Pierga(Université Paris Cité), Tineke J. Smilde(Champalimaud Foundation), Fátima Cardoso(Breast Cancer Alliance), Alastair M. Thompson(Baylor College of Medicine), Suzan Vrijaldenhoven(Noordwest Ziekenhuisgroep), Peter Vuylsteke(Champalimaud Foundation), Isabel T. Rubio(Clinica Universidad de Navarra), S. Causeret(Centre Georges François Leclerc), Josephine Lopes Cardozo(The Netherlands Cancer Institute), Aleksandra Peric(European Organisation for Research and Treatment of Cancer), Khalil Zaman, Annuska M. Glas(Leiden University Medical Center), Christos Sotiriou(Université Libre de Bruxelles), Florentine Hilbers(Breast International Group), Bart Meulemans(Champalimaud Foundation), Gabriele Zoppoli(Ospedale Policlinico San Martino), Peter A. Neijenhuis(Champalimaud Foundation), Erika Matos(Champalimaud Foundation), Mauro Delorenzi(SIB Swiss Institute of Bioinformatics), Jan Bogaerts(European Organisation for Research and Treatment of Cancer), Peter M. Ravdin(The University of Texas MD Anderson Cancer Center), Suzette Delaloge(Institut Gustave Roussy), Giuseppe Viale(University of Milan), Sherko Kümmel(Kliniken Essen-Mitte), Susan Knox(Champalimaud Foundation), Étienne Brain(Institut Curie), Konstantinos Tryfonidis(Champalimaud Foundation), Debora Fumagalli(Université Libre de Bruxelles)
Cited by 355
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k